 |
Edelman represents Amgen as it moves to acquire Horizon Therapeutics for $27.8B, making it the biggest healthcare deal for the year.
Horizon produces medicines for rare autoimmune and severe inflammatory diseases. Tepezza, its top drug, treats thyroid eye disease, and helped boost Horizon’s revenues up 47 percent to $3.2B during the past year.
Robert Bradway, Amgen’s CEO, said the deal fits his company’s “strategy of delivering long-term growth by providing innovative medicines that address the needs of patients who suffer from serious diseases.”
He also noted that drugs in Horizon’s pipeline complement Amgen’s R&D portfolio.
Horizon disclosed last month that it was considering takeover offers from Johnson & Johnson and Sanofi.
Dublin-based Amgen trades on the NASDAQ.
Lex Suvanto, CEO of Edelman financial communications; Jamaal Mobley, executive VP; and Shannon Susko, Edelman Smithfield healthcare head, are working on the deal.
They are joined by Edelman Ireland CEO Joe Carmody, corporate head Piaras Kelly and Edelman Global Advisory managing director Feargal Purcell.
Joele Frank handles Crinetics Pharmaceuticals as the specialist for treatments for endocrine diseases agrees to get acquired by Vertex Pharmaceuticals in a deal pegged at $8.8B.
Teneo represents Honeywell spin-off Solstice Advanced Materials as it buys Collected Strategies client Element Solutions in a deal pegged at $14.5B.
Dallas-based Throughline Global Advisors advised Principal Mineral as it acquired Isola Group, maker of copper-clad laminates used in printed circuit boards.
oele Frank works for satellite operator Iridium Communications as it gets acquired by space company Rocket Lab in a deal worth $8B.
Uber’s Mike Lucarelli is moving to NXP Semiconductors as senior VP-investor relations.
